LTPA2019011I1 - CGRP antikūnai - Google Patents

CGRP antikūnai

Info

Publication number: LTPA2019011I1
Authority: LT; Lithuania
Prior art keywords: cgrp antibodies; cgrp; antibodies
Prior art date: 2010-06-10

Application number

LTPA2019011C

Other languages

English (en)

Original Assignee

Eli Lilly And Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-06-10

Filing date

2019-04-12

Publication date

2019-05-10

2019-04-12 Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company

2019-05-10 Publication of LTPA2019011I1 publication Critical patent/LTPA2019011I1/lt

2020-03-25 Publication of LTC2579894I2 publication Critical patent/LTC2579894I2/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57527—Calcitonin gene related peptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57545—Neuropeptide Y
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Mycology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Microbiology (AREA)
Toxicology (AREA)
Orthopedic Medicine & Surgery (AREA)
Zoology (AREA)
Physical Education & Sports Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

LTPA2019011C 2010-06-10 2019-04-12 CGRP antikūnai LTC2579894I2 (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US35332310P	2010-06-10	2010-06-10
PCT/US2011/039381 WO2011156324A1 (en)	2010-06-10	2011-06-07	Cgrp antibodies

Publications (2)

Publication Number	Publication Date
LTPA2019011I1 true LTPA2019011I1 (lt)	2019-05-10
LTC2579894I2 LTC2579894I2 (lt)	2020-03-25

Family

ID=45096388

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP11792989.3T LT2579894T (lt)	2010-06-10	2011-06-07	Cgrp antikūnai
LTPA2019011C LTC2579894I2 (lt)	2010-06-10	2019-04-12	CGRP antikūnai

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LTEP11792989.3T LT2579894T (lt)	2010-06-10	2011-06-07	Cgrp antikūnai

Country Status (33)

Country	Link
US (3)	US9073991B2 (lt)
EP (2)	EP3318272B1 (lt)
JP (2)	JP6021806B2 (lt)
KR (1)	KR101489566B1 (lt)
CN (2)	CN104292332B (lt)
AR (1)	AR081434A1 (lt)
AU (1)	AU2011265050B2 (lt)
BR (1)	BR112012031501B1 (lt)
CA (1)	CA2802102C (lt)
CY (2)	CY1119789T1 (lt)
DK (1)	DK2579894T3 (lt)
EA (1)	EA022931B1 (lt)
ES (2)	ES2930321T3 (lt)
HR (1)	HRP20171992T1 (lt)
HU (2)	HUE038135T2 (lt)
IL (2)	IL222885B (lt)
JO (1)	JO3330B1 (lt)
LT (2)	LT2579894T (lt)
LU (1)	LUC00112I2 (lt)
ME (1)	ME02862B (lt)
MX (2)	MX340999B (lt)
NL (1)	NL300979I2 (lt)
NO (2)	NO2579894T3 (lt)
NZ (1)	NZ603607A (lt)
PL (1)	PL2579894T3 (lt)
PT (1)	PT2579894T (lt)
RS (1)	RS56638B1 (lt)
SG (1)	SG185648A1 (lt)
SI (1)	SI2579894T1 (lt)
TW (1)	TWI423818B (lt)
UA (1)	UA109658C2 (lt)
WO (1)	WO2011156324A1 (lt)
ZA (1)	ZA201208996B (lt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1957106B2 (en)	2005-11-14	2019-07-24	Teva Pharmaceuticals International GmbH	Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
JP5537441B2 (ja)	2008-03-04	2014-07-02	ファイザー・リミテッド	慢性疼痛を治療する方法
KR101519192B1 (ko)	2009-08-28	2015-05-11	리나트 뉴로사이언스 코프.	칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법
JO3330B1 (ar) *	2010-06-10	2019-03-13	Lilly Co Eli	الأجسام المضادة cgrp
DK2709663T3 (da)	2011-05-20	2019-05-20	Alderbio Holdings Llc	Anvendelse af anti-CGRP-antistoffer og antistoffragmenter til forebyggelse eller inhibering af fotofobi eller aversion mod lys hos individer med behov herfor, især migrænikere
SG10201604040PA (en)	2011-05-20	2016-07-28	Alderbio Holdings Llc	Anti-cgrp compositions and use thereof
US9855332B2 (en)	2011-05-20	2018-01-02	Alderbio Holdings Llc	Use of anti-CGRP antibodies and antibody fragments to treat diarrhea in subjects with diseases or treatments that result in elevated CGRP levels
KR102134088B1 (ko)	2012-08-24	2020-07-14	더 리젠츠 오브 더 유니버시티 오브 캘리포니아	Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
US20170114122A1 (en)	2015-10-23	2017-04-27	Alderbio Holdings Llc	Regulation of glucose metabolism using anti-cgrp antibodies
SI3119431T1 (sl)	2014-03-21	2024-06-28	Teva Pharmaceuticals International Gmbh	Antagonistična protitelesa, usmerjena proti peptidu, povezanemu z genom za kalcitonin, in postopki za uporabo le-teh
US10556945B2 (en) *	2014-03-21	2020-02-11	Teva Pharmaceuticals International Gmbh	Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MX382408B (es)	2014-10-24	2025-03-13	Merck Sharp & Dohme Llc	Coagonistas de los receptores de glucagón y de glp-1.
TWI595006B (zh) *	2014-12-09	2017-08-11	禮納特神經系統科學公司	抗ｐｄ－１抗體類和使用彼等之方法
JOP20200116A1 (ar)	2015-04-24	2017-06-16	Amgen Inc	طرق لعلاج أو الوقاية من الصداع النصفي
AR104847A1 (es) *	2015-06-17	2017-08-16	Lilly Co Eli	Formulación de anticuerpo anti-cgrp
WO2017074428A1 (en) *	2015-10-30	2017-05-04	Eli Lilly And Company	Anti-cgrp/anti-il-23 bispecific antibodies and uses thereof
CN105483091A (zh) *	2015-12-29	2016-04-13	天津三箭生物技术股份有限公司	小鼠抗人Calcitonin单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株
KR20180091930A (ko) *	2016-01-28	2018-08-16	일라이 릴리 앤드 캄파니	Cgrp 항체 및 그의 용도
CN108601833B (zh)	2016-02-01	2022-11-15	伊莱利利公司	甲状旁腺激素-抗rankl抗体融合化合物
US10688181B2 (en)	2016-06-27	2020-06-23	The Regents Of The University Of California	Cancer treatment combinations
PE20191148A1 (es)	2016-09-23	2019-09-02	Teva Pharmaceuticals Int Gmbh	Tratamiento de la migrana refractaria
MX2019003338A (es)	2016-09-23	2019-09-26	Teva Pharmaceuticals Int Gmbh	Tratamiento de cefalea en racimos.
US10766952B2 (en)	2017-03-02	2020-09-08	Beth Israel Deaconess Medical Center, Inc.	Methods for reducing migraine frequency in a subject in need thereof
TW201902926A (zh) *	2017-05-03	2019-01-16	美商美國禮來大藥廠	抗cgrp／抗il-23雙特異性抗體及其用途
US11426706B2 (en)	2017-06-21	2022-08-30	Cephalon, Inc.	Cation exchange chromatography wash buffer
TWI754772B (zh) *	2017-09-06	2022-02-11	美商美國禮來大藥廠	用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
JP7339262B2 (ja)	2018-01-12	2023-09-05	アムジェンインコーポレイテッド	Ｐａｃ１抗体及びその使用
WO2019231800A1 (en)	2018-05-31	2019-12-05	Eli Lilly And Company	Anti-cgrp antibodies for treating menstrual-related migraines
US20210340230A1 (en)	2018-08-22	2021-11-04	Eli Lilly And Company	Anti-CGRP Antibodies For Treatment-Resistant Patients
CR20210373A (es)	2019-01-08	2021-08-19	H Lundbeck As	Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp
EP3744400A1 (en) *	2019-05-28	2020-12-02	Etablissement Français du Sang	Car-t cells targeting il-1rap and their use in acute myeloid leukemia (aml)
CN114127110B (zh) *	2019-05-30	2022-07-01	山东博安生物技术股份有限公司	抗cgrp抗体及其应用
CA3154522A1 (en)	2019-10-15	2021-04-22	Christopher Carl Frye	Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
AU2020202454A1 (en)	2020-04-06	2021-10-21	H. Lundbeck A/S	Treatment of most bothersome symptom (MBS) associated with migraine using anti-CGRP antibodies
EP4301362A1 (en)	2021-03-02	2024-01-10	CGRP Diagnostics GmbH	Treatment and/or reduction of occurrence of migraine
AU2023223603A1 (en)	2022-02-28	2024-08-22	Tridem Bioscience Gmbh & Co Kg	A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN.
EP4570913A1 (en) *	2022-08-11	2025-06-18	Shanghai Junshi Biosciences Co., Ltd.	Anti-cgrp antibody and use
CN118271438B (zh) *	2024-05-27	2024-08-30	上海宏成药业有限公司	抗cgrp抗体或其抗原结合片段及其用途
CN119320450B (zh) *	2024-12-13	2025-07-25	中国人民解放军军事科学院军事医学研究院	针对降钙素基因相关肽的抗体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
JP3370324B2 (ja) *	1991-04-25	2003-01-27	中外製薬株式会社	ヒトインターロイキン−６受容体に対する再構成ヒト抗体
JP4124480B2 (ja) *	1991-06-14	2008-07-23	ジェネンテック・インコーポレーテッド	免疫グロブリン変異体
WO2005035753A1 (ja)	2003-10-10	2005-04-21	Chugai Seiyaku Kabushiki Kaisha	機能蛋白質を代替する二重特異性抗体
CA2603940A1 (en) *	2005-04-08	2006-10-19	Nancy Ulbrandt	Antibodies against mammalian metapneumovirus
EP1957106B2 (en) *	2005-11-14	2019-07-24	Teva Pharmaceuticals International GmbH	Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2007076336A1 (en) *	2005-12-22	2007-07-05	Eli Lilly And Company	Treatment of migraine with anti-cgrp antibodies
JP5537441B2 (ja) *	2008-03-04	2014-07-02	ファイザー・リミテッド	慢性疼痛を治療する方法
CA2716799C (en) *	2008-03-04	2018-05-22	Pfizer Limited	Methods of treating inflammatory pain
JO3330B1 (ar) *	2010-06-10	2019-03-13	Lilly Co Eli	الأجسام المضادة cgrp

2011
- 2011-05-31 JO JOP/2011/0177A patent/JO3330B1/ar active
- 2011-05-31 AR ARP110101867A patent/AR081434A1/es active IP Right Grant
- 2011-06-03 TW TW100119683A patent/TWI423818B/zh active
- 2011-06-07 DK DK11792989.3T patent/DK2579894T3/en active
- 2011-06-07 PL PL11792989T patent/PL2579894T3/pl unknown
- 2011-06-07 EA EA201270769A patent/EA022931B1/ru not_active IP Right Cessation
- 2011-06-07 CN CN201410474677.9A patent/CN104292332B/zh active Active
- 2011-06-07 SI SI201131359T patent/SI2579894T1/en unknown
- 2011-06-07 MX MX2012014480A patent/MX340999B/es active IP Right Grant
- 2011-06-07 RS RS20171265A patent/RS56638B1/sr unknown
- 2011-06-07 ES ES17201603T patent/ES2930321T3/es active Active
- 2011-06-07 JP JP2013514281A patent/JP6021806B2/ja active Active
- 2011-06-07 PT PT117929893T patent/PT2579894T/pt unknown
- 2011-06-07 US US13/154,538 patent/US9073991B2/en active Active
- 2011-06-07 ME MEP-2017-280A patent/ME02862B/me unknown
- 2011-06-07 KR KR1020127032068A patent/KR101489566B1/ko active Active
- 2011-06-07 WO PCT/US2011/039381 patent/WO2011156324A1/en not_active Ceased
- 2011-06-07 MX MX2016005150A patent/MX363209B/es unknown
- 2011-06-07 EP EP17201603.2A patent/EP3318272B1/en active Active
- 2011-06-07 HR HRP20171992TT patent/HRP20171992T1/hr unknown
- 2011-06-07 AU AU2011265050A patent/AU2011265050B2/en active Active
- 2011-06-07 SG SG2012084885A patent/SG185648A1/en unknown
- 2011-06-07 NO NO11792989A patent/NO2579894T3/no unknown
- 2011-06-07 CA CA2802102A patent/CA2802102C/en active Active
- 2011-06-07 NZ NZ603607A patent/NZ603607A/en unknown
- 2011-06-07 BR BR112012031501-3A patent/BR112012031501B1/pt active IP Right Grant
- 2011-06-07 ES ES11792989.3T patent/ES2656000T3/es active Active
- 2011-06-07 EP EP11792989.3A patent/EP2579894B1/en active Active
- 2011-06-07 HU HUE11792989A patent/HUE038135T2/hu unknown
- 2011-06-07 LT LTEP11792989.3T patent/LT2579894T/lt unknown
- 2011-06-07 CN CN201180028611.1A patent/CN102946905B/zh active Active
- 2011-07-06 UA UAA201212663A patent/UA109658C2/ru unknown
2012
- 2012-11-05 IL IL222885A patent/IL222885B/en active Protection Beyond IP Right Term
- 2012-11-28 ZA ZA2012/08996A patent/ZA201208996B/en unknown
2015
- 2015-06-04 US US14/730,270 patent/US9505838B2/en active Active
- 2015-11-02 IL IL242409A patent/IL242409B/en active IP Right Grant
2016
- 2016-06-28 JP JP2016127666A patent/JP6466883B2/ja active Active
- 2016-11-02 US US15/341,166 patent/US20170073403A1/en not_active Abandoned
2018
- 2018-01-18 CY CY20181100064T patent/CY1119789T1/el unknown
2019
- 2019-04-02 HU HUS1900020C patent/HUS1900020I1/hu unknown
- 2019-04-02 CY CY2019017C patent/CY2019017I1/el unknown
- 2019-04-05 NO NO2019017C patent/NO2019017I1/no unknown
- 2019-04-09 LU LU00112C patent/LUC00112I2/fr unknown
- 2019-04-11 NL NL300979C patent/NL300979I2/nl unknown
- 2019-04-12 LT LTPA2019011C patent/LTC2579894I2/lt unknown

Also Published As

Publication number	Publication date
CN104292332B (zh)	2019-11-01
ES2930321T3 (es)	2022-12-09
NL300979I1 (nl)	2019-04-17
JP2013532143A (ja)	2013-08-15
MX2012014480A (es)	2013-02-07
WO2011156324A1 (en)	2011-12-15
AU2011265050B2 (en)	2013-06-27
IL242409B (en)	2020-07-30
JP2017014203A (ja)	2017-01-19
LTC2579894I2 (lt)	2020-03-25
RS56638B1 (sr)	2018-03-30
HK1203211A1 (en)	2015-10-23
JP6021806B2 (ja)	2016-11-09
CY2019017I2 (el)	2020-05-29
NL300979I2 (nl)	2019-07-11
NO2019017I1 (no)	2019-04-05
EP2579894B1 (en)	2017-11-22
BR112012031501B1 (pt)	2020-02-11
US20110305711A1 (en)	2011-12-15
TWI423818B (zh)	2014-01-21
AU2011265050A1 (en)	2012-11-08
EA022931B1 (ru)	2016-03-31
ZA201208996B (en)	2014-05-28
ES2656000T3 (es)	2018-02-22
EA201270769A1 (ru)	2013-04-30
CA2802102C (en)	2016-07-26
KR101489566B1 (ko)	2015-02-03
TW201210618A (en)	2012-03-16
CY1119789T1 (el)	2018-06-27
EP3318272A1 (en)	2018-05-09
NZ603607A (en)	2014-09-26
EP2579894A4 (en)	2013-12-04
AR081434A1 (es)	2012-08-29
CN104292332A (zh)	2015-01-21
NO2579894T3 (lt)	2018-04-21
HUE038135T2 (hu)	2018-09-28
CN102946905B (zh)	2014-10-15
UA109658C2 (xx)	2015-09-25
US9505838B2 (en)	2016-11-29
MX340999B (es)	2016-08-03
JO3330B1 (ar)	2019-03-13
IL222885B (en)	2019-09-26
KR20130034024A (ko)	2013-04-04
LT2579894T (lt)	2018-02-26
HRP20171992T1 (hr)	2018-02-09
CN102946905A (zh)	2013-02-27
EP2579894A1 (en)	2013-04-17
DK2579894T3 (en)	2018-01-15
CY2019017I1 (el)	2020-05-29
EP3318272B1 (en)	2022-08-10
CA2802102A1 (en)	2011-12-15
US20150259415A1 (en)	2015-09-17
SI2579894T1 (en)	2018-01-31
HUS1900020I1 (hu)	2019-05-28
JP6466883B2 (ja)	2019-02-06
ME02862B (me)	2018-04-20
US9073991B2 (en)	2015-07-07
PT2579894T (pt)	2018-02-06
LUC00112I2 (lt)	2019-12-27
US20170073403A1 (en)	2017-03-16
BR112012031501A2 (pt)	2016-10-25
PL2579894T3 (pl)	2018-04-30
MX363209B (es)	2019-03-14
IL222885A0 (en)	2012-12-31
SG185648A1 (en)	2012-12-28
LUC00112I1 (lt)	2019-04-10

Publication	Publication Date	Title
LTC2579894I2 (lt)	2020-03-25	CGRP antikūnai
HUS2300021I1 (hu)	2023-07-28	Anti-IL-36R antitestek
BR112012030311A2 (pt)	2017-01-24	anticorpo
PT2530091T (pt)	2018-05-17	Anticorpo anti-dll3
IL222272B (en)	2018-04-30	Anti-erbb3 antibodies
DK2521736T3 (da)	2019-10-28	Humaniserede antistoffer
CO6811812A2 (es)	2013-12-16	Anticuerpo anti-b7-h3
BR112013010688A2 (pt)	2016-08-09	anticorpos anti c-met
LT3284754T (lt)	2021-01-25	Antikūnai prieš cd38
PT2406284T (pt)	2016-09-29	Anticorpos anti-bcma
CO6791565A2 (es)	2013-11-14	Anticuerpos anti-notch1
DK3741883T5 (da)	2024-08-26	Antistofbiblioteker
DK3178851T3 (da)	2020-07-27	Anti-cd40-antistoffer
CR20140127A (es)	2014-08-20	Anticuerpo anti-abtcr
EP2473531A4 (en)	2013-05-01	Anti-gitr antibodies
EP2482848A4 (en)	2013-04-17	Endoglin antibodies
CR20130228A (es)	2013-09-18	Anticuerpos neutralizadores anti-ccl20
EP2629796A4 (en)	2015-01-28	ANTIBODY
PL3088421T3 (pl)	2019-08-30	Przeciwciała monoklonalne do zastosowania w diagnostyce i leczeniu nowotworów i choroby autoimmunologicznej
DK3202789T3 (da)	2020-05-18	Anti-vla-4-antistoffer
DE112011101333A5 (de)	2013-01-24	Parkouraufbau
EP2578316A4 (en)	2016-06-29	PIPETTE
CO6841994A2 (es)	2014-01-20	Anticuerpos